Regeneron Pharmaceuticals Inc. (REGN) and French drug-maker Sanofi (SNYNF,SNY) announced Tuesday that the companies have completed enrollment in the global Phase 3 ODYSSEY OUTCOMES trial. The companies said the trial is prospectively evaluating the potential cardiovascular or CV benefits of Praluent (alirocumab) Injection after an acute coronary syndrome or ACS.
The 18,000-patient OUTCOMES trial is expected to be completed in 2017.
ODYSSEY OUTCOMES is designed to determine whether the addition of Praluent to intensive statin therapy reduces major adverse cardiac events among patients who had previously experienced an ACS, such as a heart attack or unstable angina.
The primary endpoint evaluates the time to first occurrence of coronary heart disease death, acute myocardial infarction, hospitalization for unstable angina, or fatal and non-fatal ischemic stroke.
Patients with recent ACS were selected as the study population because they face a higher risk of recurrent events than patients with stable cardiovascular disease.
The global ODYSSEY program includes 16 Phase 3 trials conducted at more than 2,000 study centers, around the world, and once complete will evaluate more than 25,000 patients.
For comments and feedback contact: editorial@rttnews.com
Business News